MarsNews.com

Amgen Drugs May Boost Survival During a Nuclear Attack and Trips to Mars Bloomberg

Amgen Inc. (AMGN)’s Neulasta and Neupogen and a similar blood-boosting drug from Teva Pharmaceutical Industries Ltd. (TEVA) may help people survive after a nuclear attack, U.S. regulators said.
Medications known as leukocyte growth factors, which also include Sanofi (SAN)’s Leukine, may help decrease death rates from radiation exposure, Food and Drug Administration staff said today in a report. FDA staff reviewed a National Institutes of Health study on monkeys exposed to radiation that were given Neupogen. Agency advisers plan to meet May 3 to discuss whether the animal study is sufficient to approve the use for humans.